Morgan Stanley Raises argenx (ARGX) Price Target to $1,190
Key Points
- Morgan Stanley maintained an Overweight rating on argenx SE on October 23, 2026, lifting its target from $1,140 to $1,190.
- Morgan Stanley's $1,190 price target implies 35.88% upside from argenx SE's ($ARGX) current $875.76 share price.
- Shares of argenx traded recently around $875.76, holding above their 200-day moving average.
- The biotechnology company reported trailing twelve-month revenue of $5.32 billion alongside a 32.3% net profit margin.
Get argenx SE text alerts
We text you when insiders, Congress, analysts or big funds move on $ARGX.
By entering your mobile number and tapping the sign-up button, you provide express written consent to receive recurring automated text messages from TradeTexts at that number, including stock alerts about SEC filings, insider and congress trades, analyst ratings, hedge fund moves, and earnings results. Consent is not a condition of any purchase. Message frequency varies. Messages are not investment advice. Message and data rates may apply. Reply HELP for help and STOP to opt out at any time. See our Terms and Privacy Policy.
Not investment advice. TradeTexts is not a registered investment adviser, and this automated argenx SE alert may contain errors. Disclosures
On October 23, 2026, Morgan Stanley maintained its Overweight rating on argenx SE while raising its price target from $1,140.00 to $1,190.00. The update arrived alongside a flurry of target adjustments from other major Wall Street research firms covering the biotechnology company. argenx closed at $874.91 on the day of the announcement.
ARGX
argenx SE
Morgan Stanley vs. the S&P 500
Hypothetical returns from Morgan Stanley's disclosed trades, not real profit or advice. How we model this.
Morgan Stanley's Call on argenx SE
In its research note on October 23, 2026, Morgan Stanley kept an Overweight rating on argenx SE. The firm bumped its target up by $50 from a previous $1,140.00 to $1,190.00. This forward-looking view highlights continued confidence in the drug maker's portfolio of autoimmune therapies, sitting well above the stock's recent trading levels.
Other Institutional Activity in argenx SE
Jupiter Topco LLC grew its holdings by 1,237,008 shares, ending with 2,474,015 shares worth about $2,164,540,397.00. Artisan Partners Limited Partnership grew its holdings by 40,810 shares, ending with 1,508,778 shares worth about $1,320,044,919.00. Avoro Capital Advisors LLC kept its holdings unchanged, ending with 1,000,000 shares worth about $874,909,973.00. RTW Investments LP kept its holdings unchanged, ending with 709,446 shares worth about $620,701,380.00.
argenx SE Stock Down 1.6%
argenx shares recently traded around $875.76, up about 0.1% from their event-day close of $874.91 on October 23, 2026. The stock sits about 8.1% below its 50-day moving average of $952.65, yet remains about 2.8% above its 200-day moving average of $852.26. Shares trade roughly 18.4% below their 52-week high of $1,072.75 and about 32.3% above their 52-week low of $661.85. The recent price is also well below the broader analyst consensus mean price target of $1,150.91.
$ARGX price target
argenx SE daily closes and this analyst's $1,190 target. Not advice.
Recent Earnings
The company generated trailing twelve-month revenue of $5.32 billion and reported earnings of $28.87 per share. Profitability remains strong with a net margin of 32.3% and a return on equity of 23.6%.
Analysts Set New Price Targets
Wall Street firms updated their views on October 23, 2026. Guggenheim maintained a Buy rating while lowering its target from $1,185.00 to $1,120.00. Wells Fargo kept an Overweight rating and adjusted its target from $1,356.00 to $1,336.00. Evercore ISI Group maintained an Outperform rating, lifting its target from $1,078.00 to $1,090.00. Baird maintained a Neutral rating while raising its target from $823.00 to $861.00. Overall, the stock carries a consensus buy rating among 23 analysts.
About argenx SE
Based in Amsterdam, argenx SE develops treatments for severe autoimmune diseases. Its commercial lineup includes therapies like VYVGART and VYVGART HYTRULO, which target conditions such as generalized myasthenia gravis, immune thrombocytopenia, and chronic inflammatory demyelinating polyneuropathy.
Bottom Line
Morgan Stanley's target increase reflects continued institutional optimism for the drug maker's product pipeline. Investors will want to follow upcoming research updates and earnings reports to see if the stock moves closer to Wall Street's consensus targets.
Related Filing Alerts
Source: Morgan Stanley's rating change on $ARGX (Oct 23, 2026). Written by software, not financial advice. How we make alerts